-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Purpose : To determine whether atorvastatin can reduce tibial cartilage volume loss in patients with symptomatic knee osteoarthritis (OA) in a multicenter, randomized, double-blind, placebo-controlled trial .
ObjectiveObjective : In a multicenter, randomized, double-blind, placebo-controlled trial to determine whether statins atorvastatin can slow symptomatic knee osteoarthritis (OA) of the tibial cartilage volume loss of the patient.
Methods : Participants aged 40-70 were randomized to receive oral atorvastatin ( 40 mg once a day) ( n = 151 ) or matching placebo ( n = 153 )
.
The primary endpoint was the annual percentage change in tibial cartilage volume within 2 years, which was assessed using magnetic resonance imaging (MRI) .
The preset secondary endpoints are the progression of cartilage defects and bone marrow lesions within 2 years .
MethodsMethods : 40-70 year-old participants were randomized to receive oral atorvastatin ( 40 mg , once daily) ( the n-= 151 ) or matching placebo ( the n-= 153 )
Resultsresults : 304 participants in a total of 248 people (81.
ConclusionConclusion : Compared with placebo, oral atorvastatin (once daily 40 mg ) treatment did not significantly reduce the symptoms of knee OA patients 2 cartilage volume loss during the year
Wang, Y.
, Jones, G.
, Hill, C.
Wang, Y.
Leave a message here